CRIS News & Events

Reports Q4 revenue $1.14M, consensus $3.25M. Curis believes its cash and cash equivalents as of December 31, 2025, together with initial and expected gross proceeds of the January 2026 PIPE Financing Series B Warrants, should enable the company's planned operations into the second half of 2027.

Curis files to sell 107.71M shares of common stock for holders

Curis announced that it has entered into a securities purchase agreement with new and existing healthcare-focused, high-quality institutional investors and certain insiders of the company for a private placement for gross proceeds of up to $80.8M to the company, including initial gross proceeds to the company of approximately $20.2M, in each case before placement agent fees and offering expenses. The PIPE financing is expected to close on or about January 8, 2026, subject to the satisfaction of customary closing conditions. Laidlaw & Company is acting as sole placement agent for the PIPE financing.